ArraysBank INC

At a glance, the answer is clinical and descriptive: FFPE stands for Formalin-Fixed Paraffin-Embedded. To the uninitiated, this sounds like a mundane technical procedure—a recipe for preserving biological specimens in a pathology lab. However, to view FFPE merely as a preservation…

The relapse of Anaplastic Large Cell Lymphoma (ALCL) in a pediatric patient has historically been one of the most daunting scenarios in pediatric hematology. For years, the standard of care was a path of escalation: salvage chemotherapy followed by a…

In the landscape of pediatric oncology, few narratives are as compelling as the trajectory of Anaplastic Large Cell Lymphoma (ALCL). For decades, the medical community has viewed this rare T-cell lymphoma through the narrow lens of survival statistics, celebrating a…

In the realm of hematopathology, few dichotomies have been as stark or as influential as the distinction between ALK-positive and ALK-negative Anaplastic Large Cell Lymphoma (ALCL). For years, the prognostic narrative was simple: ALK-positive patients were the lucky ones, boasting…

For decades, the treatment landscape for Peripheral T-Cell Lymphomas (PTCL) was painted with the broad, clumsy brushstrokes of anthracycline-based chemotherapy. Anaplastic Large Cell Lymphoma (ALCL), a distinct and aggressive subtype of T-cell lymphoma characterized by the expression of CD30, was…

The skin is the body’s largest organ and its most visible narrator, often telling stories of internal health through rashes, spots, and blemishes. However, not all skin tales are easy to read. Primary Cutaneous Anaplastic Large Cell Lymphoma (PC-ALCL) is…

In the intricate landscape of hematological malignancies, few stories are as compelling as the narrative of Anaplastic Large Cell Lymphoma (ALCL). This aggressive T-cell lymphoma, characterized by its peculiar “hallmark cells” with eccentric, horseshoe-shaped nuclei, presents a formidable challenge. However,…

For decades, the landscape of advanced adenoid cystic carcinoma (ACC) has been a desolate and frustrating territory for both patients and oncologists. Traditional chemotherapy, the blunt instrument of the cancer arsenal, has proven largely ineffective against this notoriously chemo-resistant tumor.…

In the lexicon of oncology, the terms “benign” and “malignant” are often presented as a stark binary: a simple, slow-growing lump versus a rampant, life-consuming disease. We are taught to fear the rapid, the aggressive, the overtly destructive. But what…

For a patient with head and neck adenoid cystic carcinoma (ACC), the words “we got it all” from a surgeon are a moment of profound, yet fragile, relief. It is a summit reached, a battle won. But for those who…